2022International Journal of Health Sciences and ResearchRequires access

Prognosis and Therapeutic Biomarker in the Management of Gastric Adenocarcinoma in Brazzaville

Fidele Mambouene, Dimitry Moudiongui

Open publisher page 0 citations

Abstract

Introduction: Gastric cancer is predominantly represented by adenocarcinoma, which is the most common histological type. The latter develops from the gastric epithelium and remains a global public health problem. The aim of the study was to assess the overexpression of the Her2 biomarker of gastric adenocarcinoma in Brazzaville. Materials and Methods: Samples of gastric carcinomatous tissues (paraffin blocks) were analyzed by the manual immunohistochemistry technique for the evaluation of the Her2 biomarker. Samples were collected retrospectively between January 2008 and December 2018. Results: during this period, 52 samples were analyzed. The immunohistochemistry results show that the Her2 protein positivity rate in adenocarcinoma cases was 9.6%. Conclusion: The results obtained during this preliminary study confirm the presence of the Her2 biomarker in 9.6% of gastric adenocarcinoma cases, which is consistent with the data in the literature. Key words: Her2, Gastric adenocarcinoma, Immunohistochemistry.

About this research paper

What this paper is about

Introduction: Gastric cancer is predominantly represented by adenocarcinoma, which is the most common histological type. The latter develops from the gastric epithelium and remains a global public health problem. The aim of the study was to assess the overexpression of the Her2 biomarker of gastric adenocarcinoma in Brazzaville. Materials and Methods: Samples of gastric carcinomatous tissues (paraffin blocks) were analyzed by the manual immunohistochemistry technique for the evaluation of the Her2 biomarker. Samples were collected retrospectively between January 2008 and December 2018. Results: during this period, 52 samples were analyzed. The immunohistochemistry results show that the Her2 protein positivity rate in adenocarcinoma cases was 9.6%. Conclusion: The results obtained during this preliminary study confirm the presence of the Her2 biomarker in 9.6% of gastric adenocarcinoma cases, which is consistent with the data in the literature. Key words: Her2, Gastric adenocarcinoma, Immunohistochemistry.

Why it matters

A significance statement is not available in the OpenAlex record.

Key contribution

A contribution statement is not available in the OpenAlex record.

Method / approach

Method details are not available in the OpenAlex metadata.

Main findings

Findings are not separately available in the OpenAlex metadata.

Limitations

Limitations are not available in the OpenAlex metadata.

Applications

Application details are not available in the OpenAlex metadata.

Available abstract

Introduction: Gastric cancer is predominantly represented by adenocarcinoma, which is the most common histological type. The latter develops from the gastric epithelium and remains a global public health problem. The aim of the study was to assess the overexpression of the Her2 biomarker of gastric adenocarcinoma in Brazzaville. Materials and Methods: Samples of gastric carcinomatous tissues (paraffin blocks) were analyzed by the manual immunohistochemistry technique for the evaluation of the Her2 biomarker. Samples were collected retrospectively between January 2008 and December 2018. Results: during this period, 52 samples were analyzed. The immunohistochemistry results show that the Her2 protein positivity rate in adenocarcinoma cases was 9.6%. Conclusion: The results obtained during this preliminary study confirm the presence of the Her2 biomarker in 9.6% of gastric adenocarcinoma cases, which is consistent with the data in the literature. Key words: Her2, Gastric adenocarcinoma, Immunohistochemistry.

Key concepts: Medicine, Biomarker, Adenocarcinoma, Immunohistochemistry, Cancer, Gastric adenocarcinoma, Internal medicine, Stomach

Related papers

Back to paper searchBrowse research topicsOriginal source
Prognosis and Therapeutic Biomarker in the Management of Gastric Adenocarcinoma in Brazzaville — Research Paper | ScholarLens